BioTechnologie Kursbuch Nr. 36

Berlin, 06.07.2023 – The German biotechnology sector continues to grow. The growth is steady, if not as rapid as in the Corona years. This is evidenced by the number of dedicated biotech companies in Germany, which is inching towards 1,000. Austria scored with the strengths of its location, and Swiss biotech companies won over investors despite the deteriorating investment climate. The industry needs to refocus and forge new alliances, taking into account the current political and economic challenges, climate change, resource use etc. The 36th BioTechnologie Kursbuch presents detailed data and facts on the state of the industry in the DACH region. In addition to interviews and company portraits, readers will find articles on biodiversity and biotechnology, artificial intelligence in drug research, lessons learned from the pandemic with regard to health research, the transformation of the fossil economy, as shortage of skilled workers. In addition, “biopioneers” are presented who are working on solutions for the biologisation of the economy.

Table of contents (excerpt):

  • The German biotech sector continues to grow
  • OECD: Dedicated Biotech Companies in Germany
  • Biodiversity and Biotechnology
  • AI revolutionises drug discovery
  • What can we learn from the pandemic?
  • Company portraits
  • Fossil economy in transition
  • Cell-free future in bioproduction
  • Skilled workers desperately wanted

Interviews: Dr. Peter-Hanns Zobel, Dr. Tilman Rock, Michael Carus, Prof. Dr. Hartmut Juhl, Dr. Martin Schleef

Biopioneers in focus: Max Mundt, Kristin Gutekunst, Mitchell Duffy, Thomas Brück

The BioTechnologie Kursbuch No. 36, edited by Andreas Mietzsch, is now available in German language at and everywhere books are available. (ISBN 978-3-928383-88-2).